Obesity is one of the greatest public health challenges of the twenty-first century. The World Health Organization (WHO) reports that in 2005 approximately 1.6 billion adults were overweight and at least 400 million adults were obese. The prevalence of obesity is still continuing to increase dramatically. Overweight and obese people carry a higher risk for a variety of cardiovascular diseases including hypertension, coronary heart disease, stroke and peripheral occlusive artery disease. Weight loss is considered to be the initial step which helps to prevent or to control the clinical consequences of obesity. In a great number of patients who are not able to reduce weight by means of non-pharmacological measures, drug therapy can assist in reaching the weight management targets. Drug treatment should only be considered as part of a systematic weight management program including dietary and lifestyle changes. This review summarizes current pharmacotherapeutic concepts for the treatment of obesity in adults focusing on efficacy and safety of anti-obesity drugs.
Epidemiology of obesity
Obesity is one of the greatest public health challenges of the twenty-first century. Once considered as a problem only in high-income countries, overweight and obesity are now dramatically on the rise in low-and middle-income countries, particularly in urban settings. Obesity is currently defined as a body mass index (BMI) of 30 kg/m 2 or greater, and a BMI between 25 and 29.9 kg/m 2 is termed overweight. The latest projections of the WHO indicate that globally in 2005 approximately 1.6 billion adults were overweight and at least 400 million adults were obese [WHO, 2006] . One study estimates the combined prevalence of obesity and overweight to be over 64% of the US adult population, with 4.7% reported as extreme obesity; that is, a BMI of 40 kg/m 2 or greater [Flegal et al. 2002] . The prevalence of obesity has tripled in many European countries since the 1980s, and the numbers of those affected continue to rise at an alarming rate. Obesity is already responsible for 2-8% of health costs and 10-13% of deaths in different parts of the European Region [WHO/Europe, 2005] . The WHO further estimates that by the year 2015, approximately 2.3 billion adults will be overweight and more than 700 million will be obese.
Obesity should no longer be viewed just as a cosmetic or body-image issue because it markedly reduces life expectancy [Fontaine et al. 2003 ]. There is compelling evidence that overweight people are at increased risk of a variety of diseases, including type 2 diabetes, hypertension, dyslipidemia, coronary artery disease, stroke, osteoarthritis and certain forms of cancer Bramlage et al. 2004a ] (Box 1). The therapeutic management of overweight and obesity is largely deficient, mainly in primary care [Bramlage et al. 2004b ]. Obesity-associated hypertension is especially difficult to treat and puts patients at a substantially increased risk for cardiovascular events ].
The medical effects of modest weight reduction (5-10% of total body weight) in patients with obesity-associated medical complications were assessed in a number of studies [Rippe et al. 1998 ]. These studies indicated that, for obese patients with type 2 diabetes, hypertension or hyperlipidemia, modest weight reduction appeared to improve glycemic control and reduced blood pressure and cholesterol levels, respectively. Modest weight reduction also appeared to reduce adverse clinical outcomes, including myocardial infarction, stroke and cardiovascular-related death [Oster et al. 1999] . Longevity has been demonstrated to be increased in obese individuals after weight reduction [Goldstein, 1992] . For patients who are unable to attain and maintain substantial weight reduction, modest weight loss should be recommended and even a small amount of weight loss appears to be of benefit for a substantial subset of obese patients [Snow et al. 2005] .
The role of drug treatment for weight loss Motivated patients can achieve remarkable degrees of sustained weight loss with dietary change and exercise alone [Anderson et al. 2001 ]. However, successful maintenance of the lifestyle changes which is needed for optimal bodyweight is uncommon Wadden, 1993] and the current methods for lifestyle modification alone are widely regarded as ineffective . Surgical treatment can result in impressive long-term weight loss, survival advantage, improvement in quality of life and reduced cardiovascular risk [Dixon, 2006; Sjostrom et al. 2004 ]. However, bariatric surgery is reserved for the patients with extreme obesity (BMI ! 40) or BMI ! 35 and related comorbidity [Sauerland et al. 2005] . For the enormous number of patients who are not able to reduce weight by means of nonpharmacological measures due to different reasons, drug therapy offers a reasonable option to overcome obesity. Drug therapy may be effective if given without lifestyle modification [Tong et al. 2002; Wadden et al. 2001 ], but is most effective when combined with diet, increased physical activity, and behavior modification [Wadden et al. 2001 ]. Therefore, weight-loss drugs should only be used as part of a comprehensive weight loss regimen [NIH, 2000] . In a review of long-term trials (41-year treatment and follow-up) comparing drug therapy plus a reduced-energy diet with diet-only therapy, the combined therapy was found to be more effective than diet alone in maintaining weight loss and preventing weight regain [Douketis et al. 2005 ]. If a patient has been on a combination regimen that includes nutrition therapy, physical activity and behavior modification and has not lost 1 pound (approximately 450 g) per week, additional drug therapy should be considered [ICSI, 2006] . Patients considered for pharmacotherapy should have a BMI of greater than or equal to 30, or a BMI of greater than or equal to 27 with concomitant obesity-related risk factors or diseases. Risk factors and diseases considered to be serious enough to support the additional use of drug therapy at a BMI of 27-29.9 include hypertension, dyslipidemia and type 2 diabetes. Only obese patients at increased medical and especially cardiovascular risk should be considered for weight-loss medication. Drug therapy should definitely not be used for cosmetic reasons [NIH, 2000] . Box 1. Complications associated with obesity. Drug treatment initiation Drug therapy should be started with an initial trial period to establish efficacy in a given patient. The amount of weight lost in the first 4 weeks may be used as a guide to subsequent therapy. Patients who respond to drug therapy should lose at least 2 kg in the first 4 weeks after the initiation of drug therapy [NIH, 2000] . The medication can be continued in patients meeting the above response criteria. In those patients who fail to meet the 4-week weight-loss guide, the chance of a long-term response is considered to be low [Guy-Grand et al. 1989 ] and they may be regarded as non-responders. In these patients, compliance with the medication regimen and with adjunctive therapies should be checked. In compliant patients a dosage adjustment should be considered. If the patient continues to be unresponsive to the drug, the medication should be discontinued [ICSI, 2006] . Successful therapy is characterized by weight loss in the first 6 months of therapy or weight maintenance after the initial weight-loss phase. Since obesity is a chronic disease, the short-term use of drugs is clinically not useful. In general, medications cannot be expected to continue to be effective in weight loss or weight maintenance once the drug has been stopped. Therefore, the health professional should initiate drug treatment only in the context of a long-term treatment strategy. For clinical practice it is also important to avoid medications associated with weight gain, if possible (Box 2).
Cardiovascular system
Considerable advances have been made in the development of anti-obesity agents in the last decades. Table 1 shows all drugs that were ever approved by the FDA for the treatment of obesity [FDA, 2008] . Not all of these drugs are still on the market. For instance, reported concerns about unacceptable side-effects, such as regurgitant valvular lesions of the heart [Connolly et al. 1997 ], led to the withdrawal of dexfenfluramine and fenfluramine from the market in September 1997 [Centers for Disease Control and Prevention, 1997] . No drug approved by the FDA for the long-term use remained available until November 1997, when the FDA approved sibutramine for long-term use in obesity. In April 1999, the FDA approved orlistat for long-term use. Sibutramine and orlistat have also been available in Europe since 1999 and 1998, respectively. Rimonabant received marketing approval from the European Medical Agency (EMEA) on 19 June 2006 the EMEA has recommended the suspension of the marketing authorisation for rimonabant due to safety problems [EMEA, 2008b] . In the US rimonabant has not been approved due to serious safety concerns. Thus, there are two drugs currently available in the European Union (EU) and the US for the long-term treatment of obesity and overweight. 
Sibutramine
Clinical pharmacology Sibutramine acts as a central appetite suppressant selectively inhibiting the reuptake of norepinephrine and serotonin at nerve endings and thereby inducing a sensation of fullness by amplifying satiety signals. The drug is rapidly absorbed from the gastrointestinal tract (T max of 1.2 h) following oral administration and undergoes extensive first-pass metabolism in the liver mainly via cytochrome P450 3A4 to form the pharmacologically active metabolites M 1 and M 2 . Peak plasma concentrations of M 1 and M 2 are reached within 3-4 h. At least 77% of a single oral dose of sibutramine is absorbed. The elimination half-life of parent drug is 1.1 h (M 1 ¼ 14 h and M 1 ¼ 16 h). The majority of the dose is eliminated via urine (77%) [Padwal et al. 2007b ].
The recommended initial dose of sibutramine is 10 mg once daily. In those patients with an inadequate response to sibutramine 10 mg (defined as less than 2 kg weight loss after 4 weeks treatment), the dose may be increased to 15 mg once daily, provided that sibutramine 10 mg was well tolerated. Treatment must be discontinued in patients who have not adequately responded to sibutramine 15 mg. Inadequate response is defined as a weight loss within 3 months after starting therapy less than 5% with respect to the initial body weight of the patient. Sibutramine drug therapy should not be prescribed for longer than 1 year.
Efficacy
In randomized controlled clinical trials a modest mean weight loss of 2.8-4.5 kg compared with placebo was shown on therapy with sibutramine for 3-12 months [Arterburn et al. 2004; McTigue et al. 2003; Padwal et al. 2003 ]. Patients receiving long-term sibutramine treatment (for at least 1 year and longer) lost 4.2 kg or 4.3% more weight than those taking placebo [Rucker et al. 2007] . Sibutramine treatment increased the absolute percentage of 5% and 10% body weight loss responders by 32% and 18% compared with placebo, respectively. In obese patients with type 2 diabetes a mean weight loss of 5.3 kg compared to placebo was observed [Norris et al. 2005; Vettor et al. 2005 ].
The Sibutramine Trial of Obesity Reduction and Maintenance (STORM) assessed the usefulness of sibutramine in maintaining substantial weight loss over 2 years . A 6-month treatment period with sibutramine (10 mg/day) and an individualized nutrition program produced a weight loss of more than 5% in 77% of patients. These subjects were then randomly assigned to 10 mg/day sibutramine or placebo for further 18 months. Sibutramine was increased up to 20 mg/day if weight gain reoccurred. The primary outcome measure was the number of patients at year 2 maintaining at least 80% of the weight lost between baseline and month 6. Forty-two percent of individuals in the sibutramine group and 50% in the placebo group dropped out. Forty-three percent of the sibutramine-treated patients who completed the trial maintained 80% or more of their original weight loss, compared with 16% of individuals in the placebo group.
There were no significant effects of sibutramine therapy compared with diet-only therapy on LDL cholesterol levels [Hauner et al. 2004; McNulty et al. 2003; James et al. 2000 , McMahon et al. 2000 ], but there were significant favorable effects on HDL cholesterol and triglyceride concentrations [Rucker et al. 2007; Hauner et al. 2004; Porter et al. 2004; McNulty et al. 2003; James et al. 2000 ]. Sibutramine therapy was found to improve glycemic control (lower fasting blood glucose, improved hemoglobin A1c levels) in patients with type 2 diabetes [Vettor et al. 2005; McNulty et al. 2003; Sanchez-Reyes et al. 2004 ].
Sibutramine can be used intermittently. A 52-week trial showed the same weight loss in the continuous and in the intermittent therapy group [Wirth and Krause, 2001 ]. The first group received continuous treatment with 15 mg/day for 1 year, and the other group had two 6-week periods of treatment when sibutramine was withdrawn.
Safety
Because of its mechanism as a monoamine reuptake inhibitor, sibutramine has the potential to raise blood pressure in certain patients which may counteract the blood pressure lowering effects achieved by its weight-reducing properties [Jordan et al. 2005] . Sibutramine was found to produce a slight but significant overall increase in both systolic and diastolic blood pressure in a meta-analysis of 21 trials [Kim et al. 2003 ]. According to another more recent meta-analysis [Rucker et al. 2007 ], sibutramine increased systolic blood pressure by 1.7 mmHg, diastolic blood pressure by 2.4 mmHg, and pulse rate by 4.5 bpm, compared with placebo. In some patients clinically relevant blood pressure increases can occur. In such cases the therapy should be stopped. The drug is contraindicated in patients with uncontrolled hypertension, preexisting cardiovascular disease, or tachycardia. In all patients blood pressure and heart rate should be regularly controlled.
The Sibutramine Cardiovascular OUTcomes (SCOUT) trial was a double-blind, randomized, placebo-controlled, parallel-group study investigating the effects of sibutramine 10 mg in overweight and obese patients at high risk of a cardiovascular event. All subjects were older than 55 years and had a history of manifest cardiovascular disease or type 2 diabetes mellitus. The study had an initial single-blind, 6-week lead-in period with sibutramine plus weight management as a safety screen in this risk population. The cardiovascular responses and weight loss during this period were recently reported [Torp-Pedersen et al. 2007 ]. Body weight decreased by 2.2 kg, waist circumference was reduced by 2.0 cm, systolic blood pressure fell by 3.0 mmHg and diastolic blood pressure by 1.0 mmHg. Pulse rate increased by 1.5 bpm. Less than 5% of all subjects experienced sustained increases (defined as two consecutive increases of 410% mmHg) in systolic or diastolic blood pressure. Sustained increases in pulse rate of 410 bpm were recorded by54%. The percentage of subjects who died was 0.1%, equivalent to 1.2 deaths per 100 years of exposure, which is less or similar to the death rates observed in the placebo arms of large studies with subject populations similar to SCOUT [Sever et al. 2005; Simes et al. 2002; HOPE, 1996] . Thus, 6-week treatment with sibutramine appears to be efficacious, tolerable and safe in this high-risk population for whom sibutramine is usually contraindicated and the current data from the SCOUT trial clearly challenge the current notion that sibutramine should be used with particular caution in patients with pre-existing hypertension.
The primary objective of another recently published 16-week, double-blind, placebo-controlled, randomized Hypertension-Obesity-Sibutramine (HOS) study [Scholze et al. 2007 ] was to discern the effects of different antihypertensive treatment regimens on sibutramine-induced weight loss in obese hypertensive patients. Two different strategies to lower blood pressure were studied: a combination of -blocker with thiazide diuretic treatment (metoprolol/hydrochlorothiazide) and two different combinations of calcium channel blocker and angiotensin-converting enzyme inhibitor (felodipin/ramipril vs verapamil/trandolapril). Blood pressure lowering efficacy was similar between these two treatment strategies. However, sibutramine-induced weight loss was markedly attenuated by the -blocker/thiazide diuretic treatment. Simultaneously, this treatment regimen abrogated the improvement in glucose tolerance. These findings strongly support the data from previous meta-analyses that the treatment with -blocker may promote weight gain [Sharma et al. 2001 ] and that the combinedblocker/thiazide treatment enhances the risk of developing diabetes mellitus [Mason et al. 2005] . In this study, blood pressure lowering with the antihypertensive therapies, especially diastolic blood pressure, was slightly attenuated by sibutramine treatment compared with placebo. Most typical adverse events of sibutramine are listed in Table 2 .
Orlistat

Clinical pharmacology
Orlistat is a lipase inhibitor [Siepmann and Kirch, 1998 ], which acts by partially inhibiting the hydrolysis of triglycerides into absorbable free fatty acids and monoacylglycerols, and thereby reduces caloric intake by inhibiting the absorption of dietary fats in the intestine lumen by around 30% [Hauptman et al. 1992 ].
The absorption of the drug is minimal (bioavailability less than 1%). Following oral dosing, plasma concentrations peak at approximately 8 h. Based on animal data, it is likely that orlistat is metabolized mainly within the gastrointestinal wall into inactive metabolites. Fecal excretion of the unabsorbed drug is the major route of elimination (approximately 97% of total drug ingested, 83% of that unchanged). The elimination half-life of orlistat is approximately 14-19 h [Zhi et al. 1995] .
The recommended dose of orlistat is 120 mg three times a day with each main meal containing fat (during or up to 1 h after the meal). The patient should be on a nutritionally balanced, reduced-calorie diet that contains approximately 30% of calories from fat. If a meal is occasionally missed or contains no fat, the dose of orlistat should be omitted.
Efficacy
Li and colleagues performed a meta-analysis of 29 studies of orlistat [Li et al. 2005 ]. The average age of patients enrolled in these studies was 48 years, and the average BMI was 36.7 kg/m 2 . Diet was a co-intervention in all 29 studies, and 18% of studies included exercise co-intervention. The pooled mean weight loss for orlistat-treated patients was 2.59 kg at 6 months and 2.89 kg at 12 months compared with placebo. Other metaanalyses showed similar weight loss rates with orlistat of approximately 2.8 kg over weight loss with placebo [Rucker et al. 2007; Hutton and Ferguson, 2004; McTigue et al. 2003; Padwal et al. 2003 ]. According to the review of ICSI-Work Group [ICSI, 2006] , a weight loss of at least 5% of initial body weight at 1 year is reported by 30-73% (vs 13-45% of patients taking placebo); a weight loss of at least 10% of initial body weight at 1 year is reported by 10-41% (vs 4-21% of patients taking placebo).
Although orlistat has also been discussed to be more a lifestyle drug [Lexchin, 2001] there is consistent study evidence that the drug might help to improve the overall cardiometabolic risk status in patients who are unable to lose weight on a diet [Schindler, 2007] . Orlistat therapy was shown to have positive effects on glycemic control in patients with or without type 2 diabetes.
Under the treatment with orlistat modest but significantly greater reductions in fasting blood glucose level were achieved (0.1-1.7 mmol/l) in most studies, compared to the diet-only therapy [Broom et al. 2002; Hanefeld and Sachse, 2002; Kelley et al. 2002; Miles et al. 2002; Lindgarde, 2000; Rossner et al. 2000; Davidson et al. 1999; Hollander et al. 1998; Sjostrom et al. 1998 ]. Most of the above-mentioned studies showed also the significantly greater reductions in serum cholesterol and LDL cholesterol levels (0.11-0.38 mmol/l) on orlistat therapy compared with diet-only therapy. These decreases of total cholesterol and LDL cholesterol are usually greater than those that can be reached by weight loss alone [Bray and Ryan, 2007] . That could be explained by the inhibition of dietary cholesterol absorption by orlistat [Mittendorfer et al. 2001 ]. The specific, weight-loss-independent cholesterol-lowering effect of orlistat needs to be further investigated in randomized clinical trials. In a recently updated meta-analysis [Rucker et al. 2007] , there was no significant difference between orlistat and placebo in triglyceride concentration and a slight but significant reduction in HDL cholesterol by 0.03 mmol/l. The same meta-analysis revealed a blood pressure reduction with orlistat of 1.5 mmHg systolic and 1.4 mmHg diastolic (orlistat effect minus placebo). Another metaanalysis demonstrated a significant reduction of triglycerides with orlistat treatment [Mannucci et al. 2008 ].
The XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) trial was designed to investigate the effect of adding orlistat to lifestyle changes on the incidence of the development of type 2 diabetes in obese patients ]. In patients with impaired glucose tolerance, orlistat plus lifestyle changes reduced the development of type 2 diabetes, compared with lifestyle changes alone (18.8% vs 28.8% over 4 years). Differences in the incidence of impaired glucose tolerance or diabetes were not detectable in the subgroup with normal glucose tolerance.
Safety
Because orlistat blocks some of the dietary fat from being absorbed, the fat is excreted unchanged in the feces. For this reason the adverse events of orlistat are mainly gastrointestinal such as steatorrhea, oily stool, flatulence, fecal urgency and increased defecation. Orlistat is safe for most patients. Gastrointestinal side effects are common, occurring in 15-30% of orlistat-treated patients [Rucker et al. 2007] (2-7% with placebo), but frequency and severity decrease over time , typically after 1 week, and can be reduced by careful attention to dietary fat content.
Because orlistat has been shown to reduce the absorption of fat-soluble vitamins A, D, E, K [McDuffie et al. 2002; Finer et al. 2000; Melia et al. 1996 ] and beta-carotene, a daily multivitamin supplement containing fat-soluble vitamins is recommendable ]. The supplement should be taken at least 2 h before or after the administration of orlistat, preferable at bedtime. The reduction of the absorption of fat-soluble vitamins including vitamin K by orlistat may result in a lower required dose of warfarin [MacWalter et al. 2003 ]. Caution is required when these two drugs are used concurrently. Orlistat can also reduce the absorption of cyclosporine [Zhi et al. 2002] and amiodarone [Zhi et al. 2003 ].
There has been some concern that orlistat may be associated with increased risk of colon cancer. Preliminary experiments in rats demonstrated an association of orlistat treatment with increases in colonic preneoplastic markers due to the high fat content in the distal colon [Garcia et al. 2006 ]. To date, increased risk of colon cancer was not reported from clinical studies and further research in humans is required.
In most areas orlistat is available by prescription only. In Australia and the US certain formulations of orlistat have been approved for sale without a prescription. In February 2007, the US Food and Drug Administration has granted approval for an over-the-counter (OTC) formulation of orlistat [FDA, 2007a] , to be marketed as 60 mg capsules which is half the dosage of orlistat by prescription. However, the approval of OTC orlistat has been controversially discussed by health professionals [Williams, 2007] and consumer organizations [Reinberg, 2007] . In October 2008 the EMEA has recommended that the status of a lower dose capsule (60 mg) of orlistat be switched from prescription to non-prescription in the European Union [EMEA, 2008a] .
Rimonabant
Clinical pharmacology
Rimonabant is a selective cannabinoid-1 (CB-1) receptor antagonist ]. CB-1 receptors are distributed widely throughout the body, including the brain and the areas related to feeding, fat cells and the gastrointestinal tract, while CB-2 receptors are mainly expressed in the immune system [Pagotto et al. 2006 ]. The endocannabinoid system plays an important role in the central and peripheral regulation of body weight and energy balance [Di Marzo et al. 2004] . Fasting increases the levels of endocannabinoids, which in turn exert their action on cannabinoid receptors. Similar, marijuana (tetrahydrocannabinol) stimulates the CB-1 receptor, increasing high fat and high sweet food intake.
Following multiple once-daily doses of 20 mg, maximum plasma concentrations of rimonabant are achieved in approximately 2 h with steadystate plasma levels achieved within 13 days (25 days in obese patients due to the higher volume of distribution). Rimonabant is metabolized by both CYP3A and amidohydrolase (predominantly hepatic) pathways to inactive metabolites. The drug is mainly eliminated by biliary excretion (approximately 86% of the dose is excreted in the feces as unchanged drug and metabolites). The elimination half-life is about 9 days (16 days in obese patients) [EMEA, 2007b] . The typical dose of rimonabant is 20 mg once daily to be taken in the morning before breakfast.
Rimonabant received marketing approval from the European Medical Agency (EMEA) on 19 June 19 2006, as an adjunct to diet and exercise for the treatment of obese patients (BMI ! 30 kg/m 2 ), or overweight patients (BMI427 kg/m 2 ) with associated risk factor(s), such as type 2 diabetes or dyslipidemia. Rimonabant was first available in the UK in July 2006. In October 2008 the EMEA has recommended the suspension of the marketing authorisation for rimonabant across the European Union due to safety problems [EMEA, 2008b] . Rimonabant is not available in the US because the FDA has not approved the drug due to safety concerns. Rimonabant has also been tested for smoking cessation but not approved for that indication because it was not considered to be adequately effective.
Efficacy
Rimonabant has been intensively studied in the Rimonabant In Obesity-Europe (RIO-Europe) program which included four large phase III trials. In the 12-month RIO-Europe study [Van Gaal et al. 2005] which was performed in obese patients, or individuals with overweight plus dyslipidemia or hypertension or both, CB-1-receptor blockade with 20 mg rimonabant was found to reduce body weight (À6.6 kg compared to À1.8 kg with placebo) and waist circumference. Plasma glucose-insulin homeostasis and triglyceride levels were also improved and rimonabant treatment resulted in a substantial increase in plasma HDL cholesterol levels. The improvements in HDL-cholesterol and triglycerides observed in this study could not be fully explained by the observed weight loss alone. A possible explanation for the potential weight independent effect of rimonabant on HDL-cholesterol and triglycerides might be related to the observation that rimonabant enhances adiponectin expression, an adipokine secreted by fat cells and reported to have a role in the regulation of hyperglycemia, hyperinsulinaemia, and fatty acid oxidation at the peripheral adipocyte level [Bensaid et al. 2003 ]. Thus, improved fat-cell function may be postulated as a key peripheral effect of rimonabant leading to body weight reduction and improvement in metabolic parameters, including lipids and beneficial changes in adiponectin and C-reactive protein [Van Gaal et al. 2005 ]. The dose of 5 mg rimonabant was found to be much less effective than 20 mg in the RIO-Europe as well as in other RIO-trials.
The Rimonabant in Obesity-Lipids (RIO-lipids) study [Despres et al. 2005] further explored the effect of 5 or 20 mg rimonabant in a high-risk population of patients with dyslipidemia who were overweight or obese, with a focus on metabolic risk parameters. Apart from the significant weight loss (À6.7 kg) and reduction in waist circumference (À5.8 cm) by 20 mg rimonabant per day for 1 year, compared to placebo, the treatment had additional favorable metabolic effects: significant improvements in plasma triglycerides, plasma HDL cholesterol, total cholesterol/HDL cholesterol ratio, as well as changes in LDL particle size, adiponectin levels, glucose tolerance, fasting and post-challenging insulin levels, plasma C-reactive protein levels and in the proportion of patients meeting the NCEP-ATPIII criteria for the metabolic syndrome. The improvement of adiponectin levels may have clinical relevance, since a high adiponectin level has been reported to be predictive for reduced risk of myocardial infarction and diabetes [Pischon et al. 2004; Spranger et al. 2003 ]. However, rimonabant had no effect on LDL cholesterol levels.
The 2-year Rimonabant In Obesity-North America (RIO-North America) Study [Pi-Sunyer et al. 2006 ] was the largest trial in the RIO-program and was characterized by re-randomization of the patients treated with 5 or 20 mg rimonabant in the first year, to receive placebo or to continue with rimonabant for the second year. The placebo group continued to receive placebo for year 2. Clinically significant weight loss achieved during the first year (À6.3 kg with 20 mg rimonabant vs 1.6 kg with placebo) was well maintained during year 2 in patients receiving 20 mg of rimonabant for both years. When patients treated with rimonabant at year 1 were switched to placebo in year 2, they regained almost all amount of the weight they had lost in the first year. Compared with patients who continued to receive rimonabant, patients who were switched to placebo in year 2 had increased levels of triglycerides and decreased levels of HDL cholesterol. These findings underline the fact that only continuous long-term treatment of obesity is successful in maintaining weight loss. Only continuous treatment is associated with weight loss and favorable changes in cardiometabolic risk factors such as hypertension or diabetes which are also conditions requiring continuous drug treatment.
The Rimonabant In Obesity-diabetes (RIOdiabetes) study [Scheen et al. 2006 ] assessed the 1-year efficacy and safety of 5 or 20 mg/day rimonabant therapy, accompanied by a mild hypocaloric diet and advice for increased physical activity, in overweight and obese patients with type 2 diabetes inadequately controlled by metformin or sulphonylureas (HbA1c 6.5-10.0%, mean 7.3% at baseline). After 1 year, placebo-corrected reduction of weight and HbA1c was À3.9 kg and À0.7%, respectively. There were also improvements in fasting glucose levels, HDL cholesterol, triglycerides, and non-HDL cholesterol serum levels.
In a meta-analysis of four RIO-trials [Rucker et al. 2007 ] patients receiving rimonabant lost 4.7 kg more weight compared to those taking placebo. Rimonabant treatment also significantly increased the placebo-subtracted absolute percentage of 5% and 10% responders by 33% (51% vs 18%) and 19% (26% vs 7%), respectively. Furthermore, rimonabant significantly reduced placebo subtracted waist circumference (À3.9 cm), systolic blood pressure (À1.8 mmHg), diastolic blood pressure (À1.2 mmHg), and triglyceride concentrations (À0.24 mmol/l) and increased HDL cholesterol concentrations (0.1 mmol/l). There were no significant reductions of LDL cholesterol and total cholesterol with rimonabant. Fasting glucose (À0.97 mmol/l) and HbA1c concentrations (À0.7%) were significantly reduced in diabetic patients in the RIO-diabetes trial, but not in other RIO-trials. Another metaanalysis showed similar weight loss of 4.9 kg with 20 mg rimonabant, and only 1.3 kg with 5 mg rimonabant, when compared with placebo [Curioni and Andre, 2006] . The RIO-trials were characterized by high attrition rates of approximately 40% at the end of 1 year.
The recent 6-month placebo-controlled Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients (SERENADE) in overweight/ obese treatment-naive type 2 diabetics not adequately controlled by diet therapy alone confirmed favorable effects of rimonabant 20 mg on glycemic control [Rosenstock, 2007] . Twenty milligrams of rimonabant significantly reduced HbA1c by 0.8% compared with 0.3% in the placebo group (mean baseline HbA1c 7.9%). In patients with higher baseline HbA1c level (!8.5%), greater reductions of 1.9% and 0.7% were achieved with 20 mg rimonabant or placebo, respectively. Additionally, rimonabant was associated with significant reductions in weight, waist, insulin resistance and triglycerides, and increases in HDL cholesterol and adiponectin levels.
The very recently published Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant -The Intravascular
Ultrasound Study (STRADIVARIUS) [Nissen et al. 2008] aimed to investigate whether rimonabant can reduce progression of coronary disease in patients with abdominal obesity and coronary artery disease. The patients underwent coronary intravascular ultrasonography for a clinical indication at baseline and after an 18-to 20-month treatment period. The study failed to show an effect of rimonabant on disease progression for the primary endpoint (percentage atheroma volume) but showed a favorable effect on the secondary endpoint (normalized total atheroma volume). 
Safety
On 13 June 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee concluded that the available set of study data on rimonabant failed to demonstrate enough safety and voted against recommending approval for this drug, mainly because of concerns over suicidality, depression and other related side-effects associated with the use of this drug [FDA, 2007b] . Subsequently, the manufacturer withdrew the new drug application (NDA) for rimonabant and announced a resubmission of application later in the future. The FDA report states that 26% of people given 20 mg rimonabant vs 14% of those given placebo had a psychiatric adverse event (mainly anxiety or depression) with the overall relative risk of 1.9 (95% CI 1.5-2.3). The analysis of the incidence of suicidality by FDA included all available rimonabant studies and found the OR to be 1.9 (95% CI 1.1-3.1) for 20 mg rimonabant vs placebo.
The safety issues raised in the FDA report were further addressed in a recently published metaanalysis [Christensen et al. 2007 ] of four trials of the RIO-program. According to this meta-analysis, rimonabant caused significantly more adverse events compared with placebo (OR ¼ 1.4; p ¼ 0.0007) and 1.4 times more serious adverse events (OR ¼ 1.4; p ¼ 0.03). Patients treated with 20 mg rimonabant were 2.5 times more likely to discontinue the therapy because of depressive mood disorders compared with those treated with placebo (OR ¼ 2.5; p ¼ 0.01). Furthermore, anxiety caused more patients to discontinue treatment in the 20 mg rimonabant groups than in placebo groups (OR ¼ 3.0; p ¼ 0.03). The importance of these findings is emphasized by the fact that patients with a history of severe or recurrent depression or other clinically significant psychiatric illnesses were not included in the analyzed trials. However, it should be noted that people with severe obesity have been shown to be at high risk for depression [Onyike et al. 2003 ]. In addition, patients in clinical practice are less likely to be thoroughly screened for depression disorders compared with participants in clinical trials. The recommendation of the EMEA in July 2007 to restrict the medicine's use resulted in the addition of a contraindication for patients with ongoing major depression or taking antidepressants [EMEA, 2007a] . In October 2008 the EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of rimonabant no longer outweigh its risks and EMEA has recommended the suspension of the marketing authorisation for rimonabant across the European Union [EMEA, 2008b] . The most frequent adverse events of rimonabant are nausea, dizziness, diarrhea and insomnia.
Although there is still a lack of head-to-head randomized clinical trials, rimonabant can currently be regarded as one of the most effective weightlowering agents that exerts substantial beneficial metabolic effects. A critical benefit-risk analysis including a detailed medical history in terms of potential predispositions for anxiety and depressive disorders should be performed prior to the administration of rimonabant to an individual patient in countries where the drug is still available. Increased alertness by physicians to potentially serious psychiatric adverse reactions is recommended in such cases.
Combination of anti-obesity drugs
The use of drug combinations for the treatment of obesity has not been sufficiently proven. Because sibutramine acts centrally on neurotransmitter reuptake mechanisms in the brain and orlistat works peripherally by reducing dietary fat absorption in the gastrointestinal tract, it might seem beneficial to combine these agents to achieve additional weight loss. However, a limited number of studies investigating the effect of the combination with sibutramine and orlistat [Kaya et al. 2004; Sari et al. 2004; Wadden et al. 2000] failed to demonstrate any additional weight loss with the combination therapy compared to sibutramine alone. The practice of combination drug therapy may therefore rather increase the frequency of adverse events without any increase in benefit. Therefore, it is currently recommendable to use weight-loss medications only as monotherapy [ICSI, 2006] .
Practical considerations
The initial choice of drug should be based on individual factors, mainly focusing on the individual cardiovascular risk profile, on dietary habits and on comorbidity ]. Patients with insufficient satiety or frequent snacking may benefit from the satiety-enhancing properties of sibutramine. Those who consume large amounts of fatty foods or are at high risk for developing type 2 diabetes, with high LDL cholesterol concentrations, may benefit from orlistat since this drug inhibits fat absorption and reduces LDL concentrations and the incidence of diabetes [Padwal et al. 2007b] . Special attention should also be given to the specific adverse event profile of each drug when administering it to an individual. Sibutramine is contraindicated in patients with poorly controlled hypertension and pre-existing cardiovascular disease, although this contraindication has been called into question by the results of the SCOUT trial, which showed the benefits of sibutramine in this high risk population. Orlistat should be avoided in patients with chronic diarrhea. Patient's preferences and lifestyle should also be taken into consideration since good compliance and patient adherence is the key to therapeutic success. For example, a busy or traveling lifestyle without rapid access to a toilet may lower the chances of treatment success with orlistat. Foreseeing such problems can support the choice of a centrally acting drug.
It should be considered that the effectiveness of anti-obesity agents in clinical practice may be lower than that demonstrated in controlled clinical trials. Study subjects are often more motivated and receive increased support and supervision than patients in a normal clinical or ambulatory setting. A recent population-based cohort analysis [Padwal et al. 2007a ] demonstrated very poor long-term persistence rates with orlistat and sibutramine and discontinuation rates that were much higher than those reported in clinical trials. At 6 months, 1 year and 2 years after initial prescription, persistence rates with orlistat were 18%, 6% and 2%, respectively. Corresponding rates for sibutramine were 26%, 8% and 2%, respectively. Limited efficacy, the onset of adverse events and costs are the most probable factors contributing to drug discontinuation. All anti-obesity medications are not indicated to be prescribed in pregnant and breast-feeding women. The administering of obesity drugs to children, adolescents and elderly patients is a special issue and should only be considered by expert physicians.
Alternative treatments
Numerous products, marketed as weight-loss preparations, are available to patients on an OTCbasis without a prescription. These products contain a wide range of ingredients either alone or in combination [Garrel, 2007] . Herbal preparations or other alternative treatments are not recommended as part of a weight loss program. These preparations have unpredictable amounts of active ingredients and unpredictable, and potentially harmful, effects [NIH, 2000] . For example, caffeine and ephedrine might cause modest weight loss in the short term [Shekelle et al. 2003 ], but increase the risk for serious cardiovascular adverse effects [ICSI, 2006] .
Future perspectives
The development pipeline of the industry for obesity and overweight drugs is currently well stocked. Apart of new CB-1-receptor agents [Fong et al. 2007 ] and novel lipase inhibitors [Kopelman et al. 2007] , completely new classes of medication are under development [Bloom et al. 2008; Cawthorne, 2007] . Neuropeptide-Y receptor antagonists, serotonin 2C receptor agonists, peptide YY 3-36, oxyntomodulin, melaninconcentrating hormone receptor-1 antagonists are only few instances from a number of drugs currently being proved for the treatment of obesity and overweight.
In conclusion, drug therapy can be a useful treatment strategy for well-selected obese or overweight patients, when used in a framework of a comprehensive weight loss program including dietary and lifestyle changes which should already be initiated in childhood [Schindler et al. 2008; Wagner et al. 2005] . The development of drugs that are more effective and safer, with more beneficial cardiometabolic effects than those currently available will remain challenging in the near future. The next 10 years are likely to reveal a greater understanding of complex molecular pathways involved in body weight regulation thus offering us new opportunities for the treatment and prevention of obesity. 
